ATE363285T1 - Verwendung von 2-alpha-cyano-4-alpha, 5-alpha- epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten - Google Patents

Verwendung von 2-alpha-cyano-4-alpha, 5-alpha- epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten

Info

Publication number: ATE363285T1
Authority: AT; Austria
Prior art keywords: alpha; alkyl; hydrogen; epoxyandrostan; cyano
Prior art date: 2001-04-09

Application number

AT02708546T

Other languages

English (en)

Inventor

Christopher Wood

George Margetts

Original Assignee

Stegram Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-09

Filing date

2002-04-09

Publication date

2007-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9912534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE363285(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-09 Application filed by Stegram Pharmaceuticals Ltd filed Critical Stegram Pharmaceuticals Ltd

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE363285T1 publication Critical patent/ATE363285T1/de

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
210000002966 serum Anatomy 0.000 title abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title 2
229960000890 hydrocortisone Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
230000001919 adrenal effect Effects 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
-1 ethylenedioxy Chemical group 0.000 abstract 2
229940088597 hormone Drugs 0.000 abstract 2
239000005556 hormone Substances 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
230000002459 sustained effect Effects 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Cephalosporin Compounds (AREA)

AT02708546T 2001-04-09 2002-04-09 Verwendung von 2-alpha-cyano-4-alpha, 5-alpha- epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten ATE363285T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB0108865A GB2375958B (en)	2001-04-09	2001-04-09	The use of steroids to lower the levels of cortisol

Publications (1)

Publication Number	Publication Date
ATE363285T1 true ATE363285T1 (de)	2007-06-15

Family

ID=9912534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02708546T ATE363285T1 (de)	2001-04-09	2002-04-09	Verwendung von 2-alpha-cyano-4-alpha, 5-alpha- epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten

Country Status (18)

Country	Link
US (1)	US9283235B2 (de)
EP (1)	EP1385527B2 (de)
JP (1)	JP5006502B2 (de)
AT (1)	ATE363285T1 (de)
AU (1)	AU2002242906B2 (de)
CA (1)	CA2443633C (de)
CY (1)	CY1106818T1 (de)
DE (1)	DE60220400T9 (de)
DK (1)	DK1385527T4 (de)
ES (1)	ES2287252T5 (de)
GB (1)	GB2375958B (de)
IL (2)	IL158361A0 (de)
MX (1)	MXPA03009236A (de)
NZ (1)	NZ529141A (de)
PT (1)	PT1385527E (de)
SI (1)	SI1385527T2 (de)
WO (1)	WO2002080930A1 (de)
ZA (1)	ZA200308567B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5544458B2 (ja)	2005-07-12	2014-07-09	アンピオファーマシューティカルズ，インコーポレイテッド	疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
FR2931678B1 (fr) *	2008-05-27	2010-10-01	Cll Pharma	Utilisation du trilistane pour le traitement de la depression
US9216221B2 (en)	2008-11-07	2015-12-22	University Of Sheffield	Medicament and method of diagnosis for treating subclinical Cushing's syndrome
JP5833549B2 (ja)	2009-06-22	2015-12-16	アンピオファーマシューティカルズ，インコーポレイテッド	血管透過性亢進を抑制するためのダナゾールを含む製薬組成物
SG177302A1 (en) *	2009-06-22	2012-02-28	Dmi Acquisition Corp	Methods and products for treatment of diseases
US20120263660A1 (en) *	2011-04-18	2012-10-18	Pop Test Cortisol Llc	Hair Loss Treatment
CN104968350A (zh)	2012-12-19	2015-10-07	安皮奥制药股份有限公司	疾病的治疗方法
LU506495B1 (en)	2024-03-01	2025-09-01	Alfasan Nederland B V	17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1123770A (en) *	1966-11-15	1968-08-14	Sterling Drug Inc	2-cyano-3-oxo-steroids
US3296255A (en) *	1963-11-29	1967-01-03	Sterling Drug Inc	2-cyano steroids
US3296295A (en) *	1964-05-22	1967-01-03	Squibb & Sons Inc	Norsteroids
US4029776A (en) *	1975-12-19	1977-06-14	Sterling Drug Inc.	Therapeutic composition and method of use thereof
FR2408345A1 (fr) *	1976-11-30	1979-06-08	Besins Jean Louis	Nouvelle composition a action anti-conceptionnelle
US4062954A (en) *	1976-12-27	1977-12-13	Sterling Drug Inc.	Process for using a steroid compound
US4160027A (en)	1977-12-20	1979-07-03	Sterling Drug Inc.	Steroid cyanoketones and intermediates
US4331663A (en) *	1981-06-19	1982-05-25	Sterling Drug Inc.	4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof
JPS5995300A (ja) *	1982-11-02	1984-06-01	スタ−リング・ドラッグ・インコ−ポレ−テッド	コントロ−ルされた粒度の２−シアノ−４，５−エポキシ−３−オキソ−ステロイド類およびそれらの組成物
JPS5971578U (ja) *	1982-11-04	1984-05-15	アンプ　インコ−ポレ−テツド	電気コネクタ組立体
GB8328929D0 (en)	1983-10-29	1983-11-30	Sterwin Ag	Steroid compounds
GB2155018B (en) *	1984-02-25	1988-04-07	Sterwin Ag	2x-cyano-4d,5x-epoxy-androstane -3,17-dione
GB8404980D0 (en) *	1984-02-25	1984-03-28	Sterwin Ag	Steroid compound
GB8414221D0 (en) *	1984-06-04	1984-07-11	Sterwin Ag	Unit dosage form
US4755595A (en) *	1985-11-01	1988-07-05	Sterling Drug Inc.	Enhanced production of 4,5-unsaturated steroids utilizing methanol solvation
US5795881A (en) *	1987-06-16	1998-08-18	Schering Aktiengesellschaft	Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
US4857333A (en) *	1988-05-12	1989-08-15	Harold Robert G	Food product for administering medication to animals
US5372996A (en) *	1989-03-10	1994-12-13	Endorecherche, Inc.	Method of treatment of androgen-related diseases
ZA901847B (en) *	1989-03-10	1991-10-30	Endorecherche Inc	Combination therapy for the treatment of estrogen sensitive diseases
DE19653969A1 (de) *	1996-12-20	1998-06-25	Boehringer Ingelheim Kg	Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB2345851B (en) *	2000-01-18	2004-05-26	Gavin Paul Vinson	A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) *	2000-01-21	2002-05-09	Cortendo Ab.	Compositions for delivery of a cortisol antagonist
GB0001449D0 (en)	2000-01-21	2000-03-08	Cortendo Ab	Compositions
EA005931B1 (ru)	2000-05-15	2005-08-25	Фармация Италия С.П.А.	Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты
GB0017635D0 (en)	2000-07-18	2000-09-06	Pharmacia & Upjohn Spa	Antitumor combined therapy
US20030050291A1 (en) *	2001-06-12	2003-03-13	Yadon Arad	Adrenal enzyme inhibitors

2001
- 2001-04-09 GB GB0108865A patent/GB2375958B/en not_active Expired - Lifetime
2002
- 2002-04-09 EP EP02708546A patent/EP1385527B2/de not_active Expired - Lifetime
- 2002-04-09 WO PCT/GB2002/001653 patent/WO2002080930A1/en not_active Ceased
- 2002-04-09 MX MXPA03009236A patent/MXPA03009236A/es active IP Right Grant
- 2002-04-09 DK DK02708546.3T patent/DK1385527T4/da active
- 2002-04-09 SI SI200230590T patent/SI1385527T2/sl unknown
- 2002-04-09 NZ NZ529141A patent/NZ529141A/en not_active IP Right Cessation
- 2002-04-09 US US10/474,868 patent/US9283235B2/en not_active Expired - Lifetime
- 2002-04-09 AT AT02708546T patent/ATE363285T1/de active
- 2002-04-09 AU AU2002242906A patent/AU2002242906B2/en not_active Expired
- 2002-04-09 ES ES02708546T patent/ES2287252T5/es not_active Expired - Lifetime
- 2002-04-09 IL IL15836102A patent/IL158361A0/xx unknown
- 2002-04-09 DE DE60220400T patent/DE60220400T9/de active Active
- 2002-04-09 CA CA2443633A patent/CA2443633C/en not_active Expired - Lifetime
- 2002-04-09 PT PT02708546T patent/PT1385527E/pt unknown
- 2002-04-09 JP JP2002578969A patent/JP5006502B2/ja not_active Expired - Lifetime
2003
- 2003-10-09 IL IL158361A patent/IL158361A/en active IP Right Grant
- 2003-11-03 ZA ZA2003/08567A patent/ZA200308567B/en unknown
2007
- 2007-08-14 CY CY20071101087T patent/CY1106818T1/el unknown

Also Published As

Publication number	Publication date
CY1106818T1 (el)	2012-05-23
DE60220400T3 (de)	2012-03-22
EP1385527B1 (de)	2007-05-30
JP2004529142A (ja)	2004-09-24
DE60220400T9 (de)	2012-08-30
IL158361A (en)	2013-07-31
NZ529141A (en)	2005-09-30
SI1385527T1 (sl)	2007-10-31
EP1385527A1 (de)	2004-02-04
PT1385527E (pt)	2007-08-21
ZA200308567B (en)	2006-04-29
IL158361A0 (en)	2004-05-12
GB0108865D0 (en)	2001-05-30
SI1385527T2 (sl)	2012-03-30
GB2375958A (en)	2002-12-04
ES2287252T5 (es)	2012-03-26
DE60220400T2 (de)	2008-01-31
ES2287252T3 (es)	2007-12-16
US9283235B2 (en)	2016-03-15
DE60220400D1 (de)	2007-07-12
US20040204392A1 (en)	2004-10-14
WO2002080930A1 (en)	2002-10-17
DK1385527T3 (da)	2007-10-29
DK1385527T4 (da)	2012-01-16
CA2443633C (en)	2010-06-22
AU2002242906B2 (en)	2009-07-02
GB2375958B (en)	2005-03-02
CA2443633A1 (en)	2002-10-17
EP1385527B2 (de)	2011-11-23
JP5006502B2 (ja)	2012-08-22
MXPA03009236A (es)	2004-11-12

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1385527

Country of ref document: EP

Publication	Publication Date	Title
CY1106818T1 (el)	2012-05-23	Χρηση παραγωγων 2-αλφα-κυανο-4-αλφα, 5-αλφα-εποξυανδροσταν-17-βητα -ολ-3-ονης για μειωση επιπεδων κορτιζολης ορου και για τη θεραπεια κλινικων καταστασεων που σχετιζονται με αυτη
ATE347365T1 (de)	2006-12-15	Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
RU93058524A (ru)	1996-10-10	Системы с регулируемым высвобождением и низкими дозами андрогенов, способ их получения и способ лечения с помощью этих систем
BRAIDMAN et al.	1971	Effects of sex hormones on three glucocorticoid-inducible enzymes concerned with amino acid metabolism in rat liver
ATE186913T1 (de)	1999-12-15	17-substituierte steroide, verwendbar bei behandlung von krebs
ATE548354T1 (de)	2012-03-15	Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ATE350041T1 (de)	2007-01-15	Pharmaceutishe zusammensetzung für die hormonersatztherapie
EE05025B1 (et)	2008-06-16	Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
DE60330695D1 (de)	2010-02-04	Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
ATE468109T1 (de)	2010-06-15	Liposomale abgabe von verbindungen auf vitamin-e- basis
ATE171873T1 (de)	1998-10-15	Antiglucocorticoidsteroide zur behandlung von angststörungen
Vinson et al.	2013	Addiction and the adrenal cortex
ES2078890T3 (es)	1996-01-01	Amino esteroides en c20 a c26.
ATE323084T1 (de)	2006-04-15	Für die behandlung von alzheimer krankheit geeignete makrocyclen
DE69625682D1 (de)	2003-02-13	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
HUP0401687A2 (hu)	2004-11-29	Szteroid-szulfatáz inhibitor acil-szulfonamidok és ezeket tartalmazó gyógyszerkészítmények
DE60036122D1 (de)	2007-10-04	Verwendung von eplerenon zur behandlung von restenose
HUP9903747A2 (hu)	2001-05-28	Új eljárás mometazon-furoát előállítására
EA200401210A1 (ru)	2005-08-25	Андрогенная фармацевтическая композиция и способ для лечения депрессии
MXPA05010871A (es)	2005-11-25	Metodos para administrar estrogenos y progestinas.
DE60132436D1 (de)	2008-03-06	Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
NO20045505L (no)	2005-03-04	Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser
DE50108711D1 (de)	2006-04-06	Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
WO2004093852A3 (en)	2004-12-23	Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
CA2395481A1 (en)	2001-07-26	Hormone receptor modulation